APLS רווחיות גולמית Apellis Pharmaceuticals, Inc.

סמל תאגידי ולוגו של Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals (APLS) is accelerating the development of ophthalmological agents through robotic bioscreening, minimizing manual labor. The current gross margin reflects the market reaction, fixing the metric at 90.10. High profitability is driven by the exclusivity of scalable eye medications. Meanwhile, the issuer's financial health remains stable, fully covering operating expenses and capital expenditures.

APLS רווחיות גולמית Apellis (04.07.2022 - 30.05.2026)

פילוחים אנליטיים ודוחות נתונים של חברת Apellis Pharmaceuticals Inc (APLS)

- מחיר מניה וקונצנזוס הערכת שווי:
הערכת שווי פונדמנטלית:Apellis (APLS)
מוצרים מיוצרים של Apellis Pharmaceuticals, Inc.

Gross margin measures the portion of revenue remaining after covering direct production costs, allowing for an assessment of the fundamental profitability of each unit of product sold. By analyzing gross margin fluctuations, an investor can gauge the scaling efficiency of Apellis Pharmaceuticals (APLS), as the high exclusivity of approved drugs combined with low variable production costs ensures a sharp increase in this metric upon entering global markets.